The link below shows what our competition have to say about their progress so far. They're reducing herpes lesions by around 30% - 50% and appear to be further ahead in the race.
http://www.genocea.com/platform-pipeline/pipeline/gen003-for-genital-herpes/
Now if I read our interim results correctly -- everyone in our Phase II trials should complete their vaccinations by Dec 2016. Then the final results should be announced by June 2017. Hopefully we can maintain or improve those solid 90% results throughout the Phase II trials. That's my understanding -- has anyone heard differently?
And if we do get the big announcement of "Phase II trial completed with 90% success" -- what's the process after that?
The link below shows what our competition have to say about...
Add AVR (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$18.00 |
Change
0.035(0.19%) |
Mkt cap ! $346.0M | |||
| Open | High | Low | Value | Volume |
| $18.00 | $18.00 | $17.65 | $75.19K | 4.184K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 414 | $17.80 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $18.10 | 1000 | 1 |
View Market Depth
| Last trade - 16.10pm 11/07/2024 (20 minute delay) ? |
| AVR (ASX) Chart |